Poll Results: IV P2Y12 Inhibitors in PCI for ACS

The intravenous P2Y12 inhibitor cangrelor has been available for a number of years for treatment during and post percutaneous coronary interventions. In the recent poll asking about the frequency of use, the majority of responders (56%) indicated that they never or rarely used it. Only a small minority, 17%, used intravenous P2Y12 inhibitors routinely, with a quarter of the responders stating that use was primarily in high-risk patients.

Poll Results: IV P2Y12 Inhibitors in PCI for ACS

Clinical Topics: Acute Coronary Syndromes, Invasive Cardiovascular Angiography and Intervention, Interventions and ACS

Keywords: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Receptors, Purinergic P2Y12


< Back to Listings